Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Add-on Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex: A Placebo-Controlled Randomized Clinical Trial.
Thiele EA, Bebin EM, Bhathal H, Jansen FE, Kotulska K, Lawson JA, O'Callaghan FJ, Wong M, Sahebkar F, Checketts D, Knappertz V; GWPCARE6 Study Group. Thiele EA, et al. Among authors: knappertz v. JAMA Neurol. 2021 Mar 1;78(3):285-292. doi: 10.1001/jamaneurol.2020.4607. JAMA Neurol. 2021. PMID: 33346789 Free PMC article. Clinical Trial.
Time to onset of cannabidiol (CBD) treatment effect in Lennox-Gastaut syndrome: Analysis from two randomized controlled trials.
Privitera M, Bhathal H, Wong M, Cross JH, Wirrell E, Marsh ED, Mazurkiewicz-Beldzinska M, Villanueva V, Checketts D, Knappertz V, VanLandingham K. Privitera M, et al. Among authors: knappertz v. Epilepsia. 2021 May;62(5):1130-1140. doi: 10.1111/epi.16878. Epub 2021 Apr 2. Epilepsia. 2021. PMID: 33797076 Free PMC article. Clinical Trial.
Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial.
Miller I, Scheffer IE, Gunning B, Sanchez-Carpintero R, Gil-Nagel A, Perry MS, Saneto RP, Checketts D, Dunayevich E, Knappertz V; GWPCARE2 Study Group. Miller I, et al. Among authors: knappertz v. JAMA Neurol. 2020 May 1;77(5):613-621. doi: 10.1001/jamaneurol.2020.0073. JAMA Neurol. 2020. PMID: 32119035 Free PMC article. Clinical Trial.
A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis.
Giovannoni G, Knappertz V, Steinerman JR, Tansy AP, Li T, Krieger S, Uccelli A, Uitdehaag BMJ, Montalban X, Hartung HP, Pia Sormani M, Cree BAC, Lublin F, Barkhof F. Giovannoni G, et al. Among authors: knappertz v. Neurology. 2020 Aug 25;95(8):e1027-e1040. doi: 10.1212/WNL.0000000000010284. Epub 2020 Jul 10. Neurology. 2020. PMID: 32651286 Clinical Trial.
Mortality in patients with multiple sclerosis.
Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC. Scalfari A, et al. Among authors: knappertz v. Neurology. 2013 Jul 9;81(2):184-92. doi: 10.1212/WNL.0b013e31829a3388. Neurology. 2013. PMID: 23836941 Free PMC article. Review.
Interleukin 17F level and interferon β response in patients with multiple sclerosis.
Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, Pohl C. Hartung HP, et al. Among authors: knappertz v. JAMA Neurol. 2013 Aug;70(8):1017-21. doi: 10.1001/jamaneurol.2013.192. JAMA Neurol. 2013. PMID: 23732754 Free PMC article. Clinical Trial.
61 results